The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma
Open accessAbstract
Nanoparticle-based materials, such as drug delivery vehicles and diagnostic probes, currently under evaluation in oncology clinical trials are largely not tumor selective.To be clinically successful, the next generation of nanoparticle agents should be tumor selective, nontoxic, and exhibit favorable targeting and clearance profiles.Developing probes meeting these criteria is challenging, requiring comprehensive in vivo evaluations.Here, we describe our full characterization of an approximately 7-nm diameter multimodal silica nanoparticle, exhibiting what we believe to be a unique combination of structural, optical, and biological properties.This ultrasmall cancer-selective silica particle was recently approved for a first-in-human clinical trial.Optimized for efficient renal clearance, it concurrently achieved specific tumor targeting.Dye-encapsulating particles, surface functionalized with cyclic arginine-glycine-aspartic acid peptide ligands and radioiodine, exhibited high-affinity/avidity binding, favorable tumor-to-blood residence time ratios, and enhanced tumor-selective accumulation in α v β 3 integrin-expressing melanoma xenografts in mice.Further, the sensitive, real-time detection and imaging of lymphatic drainage patterns, particle clearance rates, nodal metastases, and differential tumor burden in a large-animal model of melanoma highlighted the distinct potential advantage of this multimodal platform for staging metastatic disease in the clinical setting.and comprehensively defined according to the following set of diagnostic criteria: favorable distribution and targeting kinetics (1, 5-9), efficient renal clearance (10, 11), extended circulation (blood residence) times (5, 12, 13), pronounced tissue signal amplification (5, 6, 14), and improved tumoral penetration (15).Recently reported design criteria have been proposed for advancing targeted probes to the clinic (11).These have largely been restricted to improving renal clearance properties of inorganic particles containing inherently toxic components.The relative lack of in vivo toxicology data associated with these probes has led to persistent and valid safety concerns ( 16), prompting a number of particle-design modifications (9, 17-19), including size, composition, and surface chemistry, that promote more rapid clearance through kidney (renal) or liver (hepatic) pathways (20).While such approaches may minimize toxicity, the ultimate fate and impact of residual particles in the reticuloendothelial system (RES; liver, spleen, lymph nodes, bone marrow) remains unclear, particularly if toxicity is related to prolonged organ residence times (16, 17).Accelerated particle clearance may also preclude certain clinical applications as a result of restrictions imposed upon the available imaging period.Further, while rapid particle extravasation may facilitate clearance and delivery to tumors, reduced receptor binding (5) and increased nonspecific tissue dispersal (21, 22) may also occur, increasing image background and, potentially, toxicity by prolonging retention.Only a relatively small percentage of new imaging agents undergoing comprehensive preclinical testing potentially satisfy diagnostic criteria for translation (2).Although a number of fluo-Authorship note: Miriam Benezra and Oula Penate-Medina contributed equally to this work.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Renal clearance of quantum dots
Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476
Imaging in the era of molecular oncology
Weissleder, R., & Pittet, M. J. (2008) · Nature · doi:10.1038/nature06917 · Cited by 2,364
Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping
Kim, S., Lim, Y. T., Soltesz, E. G., De Grand, A. M., Lee, J., Nakayama, A., Parker, J. A., Mihaljevic, T., Laurence, R. G., Dor, D. M., et al. (2004) · Nature Biotechnology · doi:10.1038/nbt920 · Cited by 2,087
Stabin, M. G., Sparks, R. B., & Crowe, E. A. (2005) · PubMed · Cited by 1,350
Weissleder, R. (2006) · Science · doi:10.1126/science.1125949 · Cited by 1,112
Preparation of monodisperse silica particles: Control of size and mass fraction
Bogush, G. H., Tracy, M. A., & Zukoski, C. F. (1988) · Journal of Non-Crystalline Solids · doi:10.1016/0022-3093(88)90187-1 · Cited by 1,103
Near-infrared fluorescence: application to in vivo molecular imaging
Hilderbrand, S. A., & Weissleder, R. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.09.029 · Cited by 1,023
Bright and Stable Core−Shell Fluorescent Silica Nanoparticles
Ow, H., Larson, D. R., Srivastava, M., Baird, B. A., Webb, W. W., & Wiesner, U. (2005) · Nano Letters · doi:10.1021/nl0482478 · Cited by 932
Self-citationBurns, A., Ow, H., & Wiesner, U. (2006) · Chem. Soc. Rev. · doi:10.1039/b600562b · Cited by 849
Self-citationDesign considerations for tumour-targeted nanoparticles
Choi, H. S., Liu, W., Liu, F., Nasr, K., Misra, P., Bawendi, M. G., & Frangioni, J. V. (2010) · Nature Nanotechnology · doi:10.1038/nnano.2009.314 · Cited by 754
Cited by
Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery
Tang, F., Li, L., & Chen, D. (2012) · Advanced Materials · doi:10.1002/adma.201104763 · Cited by 2,836
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Multifunctional nanoparticles for multimodal imaging and theragnosis
Lee, D.-E., Koo, H., Sun, I.-C., Ryu, J. H., Kim, K., & Kwon, I. C. (2012) · Chem. Soc. Rev. · doi:10.1039/c2cs15261d · Cited by 1,410
Treating metastatic cancer with nanotechnology
Schroeder, A., Heller, D. A., Winslow, M. M., Dahlman, J. E., Pratt, G. W., Langer, R., Jacks, T., & Anderson, D. G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3180 · Cited by 1,159
Nanomaterials for In Vivo Imaging
Smith, B. R., & Gambhir, S. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00073 · Cited by 1,075
Cooper, J., & Giancotti, F. G. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.007 · Cited by 945
Mesoporous Silica Nanoparticles: A Comprehensive Review on Synthesis and Recent Advances
Narayan, R., Nayak, U. Y., Raichur, A. M., & Garg, S. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10030118 · Cited by 942
Zhao, L., Seth, A., Wibowo, N., Zhao, C.-X., Mitter, N., Yu, C., & Middelberg, A. P. J. (2014) · Vaccine · doi:10.1016/j.vaccine.2013.11.069 · Cited by 919
Clearance Pathways and Tumor Targeting of Imaging Nanoparticles
Yu, M., & Zheng, J. (2015) · ACS Nano · doi:10.1021/acsnano.5b01320 · Cited by 886
Croissant, J. G., Fatieiev, Y., & Khashab, N. M. (2017) · Advanced Materials · doi:10.1002/adma.201604634 · Cited by 782
Multifunctional Mesoporous Silica Nanocomposite Nanoparticles for Theranostic Applications
Lee, J. E., Lee, N., Kim, T., Kim, J., & Hyeon, T. (2011) · Accounts of Chemical Research · doi:10.1021/ar2000259 · Cited by 753
Chen, Y., Chen, H., & Shi, J. (2013) · Advanced Materials · doi:10.1002/adma.201205292 · Cited by 724
Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe
Phillips, E., Penate-Medina, O., Zanzonico, P. B., Carvajal, R. D., Mohan, P., Ye, Y., Humm, J., Gönen, M., Kalaigian, H., Schöder, H., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009524 · Cited by 712
Self-citationMesoporous silica nanoparticles in medicine—Recent advances
Mamaeva, V., Sahlgren, C., & Lindén, M. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.07.018 · Cited by 707
Pansare, V. J., Hejazi, S., Faenza, W. J., & Prud’homme, R. K. (2012) · Chemistry of Materials · doi:10.1021/cm2028367 · Cited by 706
Mesoporous silica nanoparticles for drug and gene delivery
Zhou, Y., Quan, G., Wu, Q., Zhang, X., Niu, B., Wu, B., Huang, Y., Pan, X., & Wu, C. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.01.007 · Cited by 706
Investigating the optimal size of anticancer nanomedicine
Tang, L., Yang, X., Yin, Q., Cai, K., Wang, H., Chaudhury, I., Yao, C., Zhou, Q., Kwon, M., Hartman, J. A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411499111 · Cited by 654
Transport and interactions of nanoparticles in the kidneys
Du, B., Yu, M., & Zheng, J. (2018) · Nature Reviews Materials · doi:10.1038/s41578-018-0038-3 · Cited by 649
Kim, S. E., Zhang, L., Ma, K., Riegman, M., Chen, F., Ingold, I., Conrad, M., Turker, M. Z., Gao, M., Jiang, X., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.164 · Cited by 622
Self-citationXu, M., Qi, Y., Liu, G., Song, Y., Jiang, X., & Du, B. (2023) · ACS Nano · doi:10.1021/acsnano.3c05853 · Cited by 632
Core/shell nanoparticles in biomedical applications
Chatterjee, K., Sarkar, S., Jagajjanani Rao, K., & Paria, S. (2014) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2013.12.008 · Cited by 610
Nanooncology: The future of cancer diagnosis and therapy
Thakor, A. S., & Gambhir, S. S. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21199 · Cited by 588
Wencel, D., Abel, T., & McDonagh, C. (2014) · Analytical Chemistry · doi:10.1021/ac4035168 · Cited by 541
Multifunctional Nanoparticles for Drug Delivery and Molecular Imaging
Bao, G., Mitragotri, S., & Tong, S. (2013) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071812-152409 · Cited by 536
Dawidczyk, C. M., Kim, C., Park, J. H., Russell, L. M., Lee, K. H., Pomper, M. G., & Searson, P. C. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.036 · Cited by 527
A Review of Clinical Translation of Inorganic Nanoparticles
Anselmo, A. C., & Mitragotri, S. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9780-2 · Cited by 509
Inorganic nanomaterials with rapid clearance for biomedical applications
Wang, X., Zhong, X., Li, J., Liu, Z., & Cheng, L. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00461h · Cited by 509
The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors
Izci, M., Maksoudian, C., Manshian, B. B., & Soenen, S. J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00779 · Cited by 506
Nonporous silica nanoparticles for nanomedicine application
Tang, L., & Cheng, J. (2013) · Nano Today · doi:10.1016/j.nantod.2013.04.007 · Cited by 488
Hybrid Nanoparticles for Detection and Treatment of Cancer
Sailor, M. J., & Park, J. (2012) · Advanced Materials · doi:10.1002/adma.201200653 · Cited by 487
He, Q., & Shi, J. (2014) · Advanced Materials · doi:10.1002/adma.201303123 · Cited by 482
Degradability and Clearance of Inorganic Nanoparticles for Biomedical Applications
Yang, G., Phua, S. Z. F., Bindra, A. K., & Zhao, Y. (2019) · Advanced Materials · doi:10.1002/adma.201805730 · Cited by 436
Multifunctional mesoporous silica nanoparticles for biomedical applications
Xu, B., Li, S., Shi, R., & Liu, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01654-7 · Cited by 433
Synthetic amorphous silica nanoparticles: toxicity, biomedical and environmental implications
Croissant, J. G., Butler, K. S., Zink, J. I., & Brinker, C. J. (2020) · Nature Reviews Materials · doi:10.1038/s41578-020-0230-0 · Cited by 424
Cancer drug delivery in the nano era: An overview and perspectives
Li, Z., Tan, S., Li, S., Shen, Q., & Wang, K. (2017) · Oncology Reports · doi:10.3892/or.2017.5718 · Cited by 406
Fundamentals and developments in fluorescence-guided cancer surgery
Mieog, J. S. D., Achterberg, F. B., Zlitni, A., Hutteman, M., Burggraaf, J., Swijnenburg, R.-J., Gioux, S., & Vahrmeijer, A. L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00548-3 · Cited by 389
Silica-based nanoprobes for biomedical imaging and theranostic applications
Vivero-Escoto, J. L., Huxford-Phillips, R. C., & Lin, W. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15229k · Cited by 381
Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy
Lu, Q., Kou, D., Lou, S., Ashrafizadeh, M., Aref, A. R., Canadas, I., Tian, Y., Niu, X., Wang, Y., Torabian, P., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01535-8 · Cited by 373
Cheng, Y.-H., He, C., Riviere, J. E., Monteiro-Riviere, N. A., & Lin, Z. (2020) · ACS Nano · doi:10.1021/acsnano.9b08142 · Cited by 362
Renal clearable inorganic nanoparticles: a new frontier of bionanotechnology
Liu, J., Yu, M., Zhou, C., & Zheng, J. (2013) · Materials Today · doi:10.1016/j.mattod.2013.11.003 · Cited by 351
Hu, K., Xie, L., Zhang, Y., Hanyu, M., Yang, Z., Nagatsu, K., Suzuki, H., Ouyang, J., Ji, X., Wei, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16513-0 · Cited by 346
Recent advances in metal nanoparticles in cancer therapy
Sharma, A., Goyal, A. K., & Rath, G. (2018) · Journal of Drug Targeting · doi:10.1080/1061186x.2017.1400553 · Cited by 341
Chen, F., Ehlerding, E. B., & Cai, W. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.146019 · Cited by 328
Towards clinically translatable in vivo nanodiagnostics
Park, S.-M., Aalipour, A., Vermesh, O., Yu, J. H., & Gambhir, S. S. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.14 · Cited by 327
Ultrasmall inorganic nanoparticles: State-of-the-art and perspectives for biomedical applications
Zarschler, K., Rocks, L., Licciardello, N., Boselli, L., Polo, E., Garcia, K. P., De Cola, L., Stephan, H., & Dawson, K. A. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2016.02.019 · Cited by 303
Inorganic nanoparticles in clinical trials and translations
Huang, H., Feng, W., Chen, Y., & Shi, J. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100972 · Cited by 283
Biodegradable and Renal Clearable Inorganic Nanoparticles
Ehlerding, E. B., Chen, F., & Cai, W. (2016) · Advanced Science · doi:10.1002/advs.201500223 · Cited by 277
Liu, J., Yu, M., Ning, X., Zhou, C., Yang, S., & Zheng, J. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201304465 · Cited by 276
Recent applications of immunomodulatory biomaterials for disease immunotherapy
Dai, H., Fan, Q., & Wang, C. (2022) · Exploration · doi:10.1002/exp.20210157 · Cited by 268
Rosenholm, J. M., Mamaeva, V., Sahlgren, C., & Lindén, M. (2012) · Nanomedicine · doi:10.2217/nnm.11.166 · Cited by 263
Mesoporous silica nanoparticles as antigen carriers and adjuvants for vaccine delivery
Mody, K. T., Popat, A., Mahony, D., Cavallaro, A. S., Yu, C., & Mitter, N. (2013) · Nanoscale · doi:10.1039/c3nr00357d · Cited by 261
Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery
Waheed, S., Li, Z., Zhang, F., Chiarini, A., Armato, U., & Wu, J. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01605-4 · Cited by 259
Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care
Hartshorn, C. M., Bradbury, M. S., Lanza, G. M., Nel, A. E., Rao, J., Wang, A. Z., Wiesner, U. B., Yang, L., & Grodzinski, P. (2018) · ACS Nano · doi:10.1021/acsnano.7b05108 · Cited by 258
Self-citationNanoparticle-Based Delivery Systems for Vaccines
Bezbaruah, R., Chavda, V. P., Nongrang, L., Alom, S., Deka, K., Kalita, T., Ali, F., Bhattacharjee, B., & Vora, L. (2022) · Vaccines · doi:10.3390/vaccines10111946 · Cited by 253
AbouAitah, K., Swiderska-Sroda, A., Farghali, A. A., Wojnarowicz, J., Stefanek, A., Gierlotka, S., Opalinska, A., Allayeh, A. K., Ciach, T., & Lojkowski, W. (2018) · Oncotarget · doi:10.18632/oncotarget.25470 · Cited by 83
Ultrasmall silica nanoparticles in translational biomedical research: Overview and outlook
Singh, N., Shi, S., & Goel, S. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114638 · Cited by 35
Intravital microscopy for real-time monitoring of drug delivery and nanobiological processes
Momoh, J., Kapsokalyvas, D., Vogt, M., Hak, S., Kiessling, F., van Zandvoort, M., Lammers, T., & Sofias, A. M. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114528 · Cited by 33
Yamaguchi, H., Hayama, K., Sasagawa, I., Okada, Y., Kawase, T., Tsubokawa, N., & Tsuchimochi, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030908 · Cited by 30
“Furthermore, diagnostic probes composed of silica nanoparticles have already been approved for phase 1 human clinical trials, and the first clinical trial investigating modified fluorescent core-shell silica nanoparticles is in progress [13,14].”
Background
Metadata
- Authors
- Benezra, M., Penate-Medina, O., Zanzonico, P. B., Schaer, D., Ow, H., Burns, A., DeStanchina, E., Longo, V., Herz, E., Iyer, S., Wolchok, J., Larson, S. M., Wiesner, U., & Bradbury, M. S.
- Venue
- Journal of Clinical Investigation
- Published
- 2011-07-01
- Volume
- 121
- Issue
- 7
- Pages
- 2768-2780
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2063443915
- Cited by
- 645
- References
- 51
- FWCI
- 26.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.